JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, F. T.
Right arrow Articles by Scott, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, F. T.
Right arrow Articles by Scott, A. M.
Journal of Nuclear Medicine Vol. 42 No. 5 764-769
© 2001 by Society of Nuclear Medicine

BASIC SCIENCE INVESTIGATIONS

Immuno-PET of Human Colon Xenograft– Bearing BALB/c Nude Mice Using 124I-CDR–Grafted Humanized A33 Monoclonal Antibody

Fook T. Lee, Cathrine Hall, Angela Rigopoulos, Jamal Zweit, Kunthi Pathmaraj, Graeme J. O’Keefe, Fiona E. Smyth, Sydney Welt, Lloyd J. Old and Andrew M. Scott

Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, and Centre for PET, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australia; The Royal Marsden Hospital, London, United Kingdom; and Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York

Radiolabeling monoclonal antibodies (mAbs) allows the evaluation of biodistribution of constructs in vivo through gamma camera imaging and also permits quantitation of mAb uptake in tumors through biopsy-based counting techniques. The quantitation of radiolabeled mAb uptake in cancer patients is complicated by the attenuation of gamma emissions of routinely used isotopes (e.g., 131I and 111In) and the spatial resolution and sensitivity of gamma cameras. Methods: We used the positron-emitting isotope 124I (half-life [T1/2] = 4.2 d) to label the recombinant humanized anti–colorectal cancer A33 antibody (huA33) and evaluated its biodistribution properties and PET imaging characteristics in BALB/c nude mice bearing SW1222 colorectal xenografts and control colon tumors. Results: The immunoreactivity of radioconjugate was 78% as determined using the cell-binding Lindmo assay. The apparent association constant was found to be 2.2 x 109 M-1, and the number of antibody binding sites per cell was 371,000. The radioconjugate was found to be stable in serum obtained from mice at various times after injection. Assuming a two-compartment model with a four-parameter fit of mean blood levels, the T1/2{alpha} was 1.5 h and the T1/2ß was 38.2 h. Excellent tumor uptake was obtained, with maximal uptake reaching 50.0 ± 7.0 percentage injected dose per gram of tumor by 4 d after injection. Specificity of localization was shown by lack of uptake in control tumor. PET imaging detected antigen-positive tumor by 4 h after injection, and high-resolution images were obtained by 24 h after injection. Conclusion: In clinical trials using PET, huA33 labeled with 124I has potential for imaging and staging colon tumors and quantifying antibody uptake in colon tumors in vivo.

Key Words: humanized monoclonal antibody • colorectal cancer • 124I • PET • xenografts


Related articles in JNM:

PET Imaging for Planning Cancer Therapy
Janet F. Eary
JNM 2001 42: 770-771. [Full Text]  



This article has been cited by other articles:


Home page
 The OncologistHome page
G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
Oncologist, December 1, 2007; 12(12): 1379 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. S. Wall, S. J. Kennel, M. Paulus, J. Gregor, T. Richey, J. Avenell, J. Yap, D. Townsend, D. T. Weiss, and A. Solomon
Radioimaging of Light Chain Amyloid with a Fibril-Reactive Monoclonal Antibody
J. Nucl. Med., December 1, 2006; 47(12): 2016 - 2024.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al.
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al.
Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
Clin. Cancer Res., July 1, 2005; 11(13): 4818 - 4826.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Robinson, M. Doss, C. Shaller, D. Narayanan, J. D. Marks, L. P. Adler, D. E. Gonzalez Trotter, and G. P. Adams
Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 Diabody
Cancer Res., February 15, 2005; 65(4): 1471 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
I. Verel, G. W.M. Visser, and G. A. van Dongen
The Promise of Immuno-PET in Radioimmunotherapy
J. Nucl. Med., January 1, 2005; 46(1_suppl): 164S - 171S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Sundaresan, P. J. Yazaki, J. E. Shively, R. D. Finn, S. M. Larson, A. A. Raubitschek, L. E. Williams, A. F. Chatziioannou, S. S. Gambhir, and A. M. Wu
124I-Labeled Engineered Anti-CEA Minibodies and Diabodies Allow High-Contrast, Antigen-Specific Small-Animal PET Imaging of Xenografts in Athymic Mice
J. Nucl. Med., December 1, 2003; 44(12): 1962 - 1969.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Jain and S. K. Batra
Genetically Engineered Antibody Fragments and PET Imaging: A New Era of Radioimmunodiagnosis
J. Nucl. Med., December 1, 2003; 44(12): 1970 - 1972.
[Full Text] [PDF]

Home page
 JNMHome page
I. Verel, G. W.M. Visser, R. Boellaard, M. Stigter-van Walsum, G. B. Snow, and G. A.M.S van Dongen
89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies
J. Nucl. Med., August 1, 2003; 44(8): 1271 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. T. Lee and A. M. Scott
Immuno-PET for Tumor Targeting
J. Nucl. Med., August 1, 2003; 44(8): 1282 - 1283.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Tahtis, F.-T. Lee, J. M. Wheatley, P. Garin-Chesa, J. E. Park, F. E. Smyth, Y. Obata, E. Stockert, C. M. Hall, L. J. Old, et al.
Expression and Targeting of Human Fibroblast Activation Protein in a Human Skin/Severe Combined Immunodeficient Mouse Breast Cancer Xenograft Model
Mol. Cancer Ther., August 1, 2003; 2(8): 729 - 737.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Scott, G. Wiseman, S. Welt, A. Adjei, F.-T. Lee, W. Hopkins, C. R. Divgi, L. H. Hanson, P. Mitchell, D. N. Gansen, et al.
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer
Clin. Cancer Res., May 1, 2003; 9(5): 1639 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. F. Eary
PET Imaging for Planning Cancer Therapy
J. Nucl. Med., May 1, 2001; 42(5): 770 - 771.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.